KPPK GmbH

Research site

Germany Emil-Schueller-Strasse 29, Mitte, 56068 Koblenz, Germany

Chronic obstructive pulmonary disease · Asthmatic crisis
Adult patients

About Specializations

KPPK GmbH in Koblenz, Germany specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Asthmatic crisis, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Emil-Schueller-Strasse 29, Mitte56068 KoblenzGermany

Open in maps ↗

Recruiting now: no trials
Conditions studied: 2

More sites in Koblenz Germany

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

3 clinical trials

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Tanimilast
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Roflumilast
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Human IgG1 kappa monoclonal antibody against CRLF2
Sponsor:Upstream Bio Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites